PDS Biotech will host a conference call with the company after the oral


FLORHAM PARK, NJ, May 24, 2021 (GLOBE NEWSWIRE) – PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on proprietary software from the company Versamune® T Cell Activation Technology, today announced that it will host a conference call with the company on June 8, 2021 at 8:00 a.m. ET, following the oral presentation of preliminary data from PDS0101 at the 2021 annual meeting from the American Society of Clinical Oncology (ASCO). . A press release summarizing the data from the summaries was released on May 20.

During the call, PSD Biotech will review data from the previously announced oral presentation of the National Cancer Institute (NCI) Phase 2 trial of PDS0101 in triple combination for the treatment of advanced cancers associated with HPV. . Following the presentation, PDS Biotech will hold a question-and-answer session.

The conference call is scheduled to begin at 8:00 am ET on Tuesday, June 8, 2021. Participants should dial 877-407-3088 (US) or 201-389-0927 (international) and quote PDS Biotechnology. A live webcast of the conference call will also be available at https://event.webcasts.com/starthere.jsp?ei=1467666&tp_key=7a66e126d4

Currently, the full abstract of # 2501 titled “Phase II Evaluation of the Triple Combination of PDS0101, M9241 and bintrafusp alfa in Patients with HPV 16 Positive Malignancies” is available on the ASCO meeting website. A copy of the PDS Biotech presentation will be available on June 8e on the scientific presentations and publications page of the PDS Biotech website. Registration for the conference call is now open and a live webcast of the event will be available online in the investor relations section of the company’s website at https://pdsbiotech.com/ investors / news-center / events. A replay will be available on the company’s website for 90 days after the webcast.

About PDS Biotechnology

PDS Biotech is a clinical stage immunotherapy company developing a growing portfolio of cancer immunotherapies and infectious disease vaccines based on the proprietary product of the company Versamune® Technological platform for T lymphocyte activation. Our Versamune®-based products can overcome the limitations of current immunotherapy by inducing in vivo, large amounts of high quality and highly potent polyfunctional CD4 + T cells and CD8 + killer T cells. PDS Biotech has developed several experimental therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and to attack and destroy them effectively. Our immuno-oncology product candidates are initially being studied in combination therapy to potentially improve efficacy without worsening toxicity in a range of cancer types. PDS0101, the Company’s leading investigational cancer immunotherapy product, is currently in Phase 2 clinical studies in HPV-associated cancers. To learn more, visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0101

PDS Biotech lead candidate PDS0101 combines utility of Versamune® platform with antigens targeted in cancers expressing HPV. In partnership with Merck and Co., PDS Biotech is evaluating a combination of PDS0101 and KEYTRUDA® in a phase 2 study in the first-line treatment of recurrent or metastatic head and neck cancer. PDS Biotech is also conducting two additional Phase 2 studies in advanced HPV-associated cancers and advanced localized cervical cancer with the National Cancer Institute (NCI) and the University of Texas MD Anderson Cancer Center, respectively.

Forward-looking statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) regarding PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss objectives, intentions and expectations with respect to future plans, trends, events, results of operations or financial condition, or otherwise, based on the current beliefs of the management of the company, as well as the assumptions made by and the information currently available for the management. Forward-looking statements generally include statements that are predictive in nature and depend on or refer to future events or conditions, and include words such as “may”, “will”, “should”, “would”, ” foresee ”,“ anticipate ”,” “plan”, “probable”, “believe”, “estimate”, “plan”, “intend”, “foresee”, “guide”, “outlook” and others similar expressions, among others. Forward-looking statements are based on current beliefs and assumptions which are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement due to various factors, including, without limitation: the ability of the Company to protect its intellectual property rights; the expected capital needs of the company, including the expected cash flow path of the company and the current expectations of the company regarding its future equity financing plans; the dependence of the Company on additional financing to finance its operations and complete the development and commercialization of its product candidates, and the risks that the raising of such additional capital could restrict the operations of the Company or oblige the Company to waive its rights to the Company’s technologies or product candidates; the company’s limited operating history in the company’s current line of business, making it difficult to assess the company’s prospects, the company’s business plan, or the likelihood of successful implementation of this business plan by the company; the timing chosen by the Company or its partners to launch the clinical trials planned for PDS0101, PDS0203 and other Versamune® based products; the future success of these trials; the successful implementation of the company’s research and development programs and collaborations, including collaborative studies regarding PDS0101, PDS0203 and other Versamune® the products based and the Company’s interpretation of the results and conclusions of such programs and collaborations and whether these results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and planned clinical trials for the Company’s current product candidates, including statements regarding when to launch, pace of recruitment and completion of trials (including our ability to fully fund our disclosed clinical trials, which assumes no material change from our currently projected spending), futility analyzes, conference presentations and data reported in an abstract, and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any statement from the company regarding its understanding of the mechanisms of action of product candidates and the interpretation of preclinical and early clinical results of its clinical development programs and any collaborative studies; market acceptance of the Company’s product candidates, if approved; the timing and ability of the Company to obtain and maintain the approval of the United States Food and Drug Administration or other regulatory authority or other action with respect to the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments beyond the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing consideration of material factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with the statements included herein and elsewhere, including the risk factors included in the annual and periodic reports of the company filed with the second. Forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statement, whether as a result of new information, future events or otherwise.

Media contact and investor relations:

Deanne Randolph
PDS Biotech
Telephone: +1 (908) 517-3613
Email: [email protected]

Rich cockrell
CG Capital
Telephone: +1 (404) 736-3838
Email: [email protected]pital

* Updated data and results to be presented in June at the ASCO meeting
1 CS Rumfield et al., J. Journal for Immunotherapy of Cancer 2020; 8: e000612. doi: 10.1136 / jitc-2020-000612)
2 S. Gandhapudi et al, J. Immunology, 2019 (202), 1215


About Hector Hedgepeth

Check Also

Study reveals how lack of technology can impact food insecurity

According to Professor Di Fang of the University of Arkansas, the psychological effects of food …

Leave a Reply

Your email address will not be published.